Death Eector Domains (DEDs) have been known to mediate the recruitment of Caspase 8 and its homologs to the aggregated death-inducing signaling complex (DISC), consisting of the death domain (DD)-containing receptors and various signaling proteins. In addition, several viruses were recently shown to encode proteins with DEDs (also called FLICE inhibitory proteins or vFLIPs) which have the ability of blocking cell death induced by DD-containing receptors. We provide evidence that vFLIPs can also modulate the NF-kB pathway and physically interact with several signaling proteins, such as the TRAFs, RIP, NIK and the IKKs. Modulation of the NF-kB pathway may play a role in the natural history of infection by these viruses.
Introduction
Tumor Necrosis Factor Receptor 1 (TNFR1) is the best characterized member of the TNFR family and is believed to activate two major signaling pathways: a caspase cascade leading to cell death and a kinase cascade resulting in the activation of the NF-kB and JNK/SAPK pathways ( Figure 1 ). The activation of the caspase cascade involves the recruitment of Caspase 8 (or FLICE/Mch5) to the cytoplasmic domain of TNFR1 via the adapter proteins TRADD and FADD (Boldin et al., 1995; Chinnaiyan et al., 1995 Chinnaiyan et al., , 1996 Hsu et al., 1995 Hsu et al., , 1996b Varfolomeev et al., 1996) (Figure  1 ). Caspase 8 is the apical caspase of the caspase cascade and possesses an N-terminal prodomain consisting of two homologous Death Eector Domains (DEDs) Fernandes-Alnemri et al., 1996; Muzio et al., 1996) . DEDs-containing prodomains are also found in two additional cellular proteins; Caspase 10 (Mch4, FLICE2) (FernandesAlnemri et al., 1996; Vincenz and Dixit, 1997) , and MRIT (c-FLIP, Casper, I-FLICE, FLAME, CASH, CLARP) (Goltsev et al., 1997; Han et al., 1997; Hu et al., 1997b; Inohara et al., 1997; Irmler et al., 1997; Shu et al., 1997; Srinivasula et al., 1997) . Recently, several viruses were also found to encode proteins with homology to the DEDs (Bertin et al., 1997; Hu et al., 1997a; Thome et al., 1997) . These virally encoded DEDs-containing protein (also called viral FLICE inhibitory proteins or vFLIPs) included MC159L from the Molluscum Contagiousum virus (MCV), ORF-K13 from the Kaposi Sarcoma Associated Herpes Virus/Human Herpes Virus 8 (KSHV/HHV8), and E8 from the Equine Herpes Virus 2 (EHV2). MC159L and E8 were shown to bind to the DED(s) of Caspase 8 or FADD and block cell death mediated by several DD-containing receptors (Bertin et al., 1997; Hu et al., 1997a; Thome et al., 1997) , while the antiapoptotic ability of ORF-K13 is yet to be explored.
We have recently discovered that cellular DEDscontaining proteins, such as Caspase 8, Caspase 10 and MRIT, can activate the NF-kB pathway and this ability is localized to their DEDs-containing prodomains (manuscript in preparation). In the present report, we demonstrate the dierential ability of vFLIPs encoded by the HHV8, MCV and EHV2 to activate the NF-kB pathway and discuss the implications of our results for the natural history of infection caused by these viruses.
Results
We began by testing the ability of ORF-K13, MC159L and E8 to activate an NF-kB driven reporter construct (Berberich et al., 1994) in 293T cells (T antigen transformed human embryonic kidney). As shown in Figure 2a , expression of ORF-K13 led to signi®cant activation of NF-kB whereas MC159L and E8 failed to do so. ORF-K13 failed to activate a reporter construct containing a NF-IL6 or AP1 binding-site, which demonstrated the speci®city of the assay (not shown). Activation of the NF-kB pathway by ORF-K13 was not limited to 293T cells as it also strongly activated this pathway in NIH3T3 cells (Figure 2b ). To con®rm the dierential NF-kB inducing ability of vFLIPs, we performed electrophoretic mobility shift assay on nuclear extracts from 293T cells transfected with the various vFLIPs expression constructs. As shown in Figure 2c , an inducible NF-kB complex was detected only in cells transfected with an ORF-K13 construct (lane 5) and was absent in the extracts derived from cells transfected with an empty vector, E8 or MC159L (lanes 2 ± 4). The speci®city of this inducible complex was con®rmed by competition with a cold NF-kB oligonucleotide (lane 6) or a nonspeci®c oligonucleotide (lane 7). A gel supershift assay, utilizing sub-units speci®c antibodies, demonstrated that the induced complex was a hetero-dimer of p65 and p50 sub-units of NF-kB (lanes 8 ± 11).
Previous studies have demonstrated that MC159L and E8 can bind to the adapter protein FADD via the interactions between their respective DEDs (Bertin et al., 1997; Hu et al., 1997a; Thome et al., 1997) . As ORF-K13 also possesses DEDs, it is conceivable that ORF-K13 activated the NF-kB pathway by virtue of its ability to bind to FADD with subsequent reverse signaling through the DD-containing receptors. To rule out this possibility, we tested the ability of ORF-K13 to activate NF-kB pathway in FADD7/7 embryonic ®broblasts (Yeh et al., 1998) . We used NIK, a strong inducer of the NF-kB pathway (Malinin et al., 1997) , as a positive control for this experiment since its NFkB-inducing ability is not likely to be dependent on FADD (Figure 1 ). As shown in Figure 2d , ORF-K13 was as eective as NIK in activating the NF-kB pathway in these cells. These results demonstrate that ORF-K13 can activate the NF-kB pathway independent of FADD, although they do not completely rule out a role for FADD in ORF-K13 induced NF-kB activation.
Mechanism of ORF-K13-induced NF-kB activation
To study the mechanism of NF-kB activation by ORF-K13, we tested the ability of dominant-negative constructs of several proteins involved in NF-kB signaling to block ORF-K13-induced NF-kB activation. ORF-K13-induced NF-kB activation was effectively blocked by a dominant-negative mutant of TRAF2 (amino acids 87 ± 501) (Takeuchi et al., 1996) which has been previously shown to block NF-kB induction by several members of the TNFR family ( Figure 3a) . Similarly, I-TRAF/Tank, a protein previously shown to bind to the TRAFs (Cheng and Baltimore, 1996; Rothe et al., 1996) , could block NFkB induction by ORF-K13 (Figure 3a ). Both the above proteins could also block NF-kB induction by Caspase 8 and MRIT (Figure 3a) . However, while TRAF1 was partially eective in blocking Caspase 8-induced NFkB activation and enhanced NF-kB induction by MRIT, it had only a marginal eect on NF-kB induction by ORF-K13 (Figure 3a) . Similarly, unlike MRIT, ORF-K13-induced NF-kB activation was not inhibited by caspase inhibitors CrmA and p35 ( Figure  3b and manuscript in preparation). Taken together, these results suggest that dierent DED-containing proteins activate the NF-kB pathway by similar, yet distinct, mechanisms.
TRAF2 and its homologs have been recently shown to bind to NIK, which subsequently binds to two recently identi®ed protein kinases termed I-kappa B kinase kinase 1 (IKK1 or IKKa) and 2 (IKK2 or IKKb) (Figure 1 ) (DiDonato et al., 1997; Mercurio et al., 1997; Regnier et al., 1997; Woronicz et al., 1997; Zandi et al., 1997) . As shown in Figure 3c , dominantnegative mutants of NIK and IKK2 could block NFkB activation mediated by the ORF-K13, whereas a similar mutant of IKK1 failed to do so. Control experiments demonstrated that both IKK1 and IKK2 mutant proteins were being expressed at equivalent level (data not shown). These results are in agreement with previous reports suggesting that IKK2 is more active as an inducer of the NF-kB pathway as compared to IKK1 and would indicate that IKK2 is primarily responsible for activation of the NF-kB pathway by ORF-K13 (Mercrio et al., 1997; Woronicz et al., 1997) . Alternatively, the failure of IKK1-K44M to block NF-kB induction of ORF-K13 may be related to the fact that this mutant is, in general, a much weaker inhibitor of the NF-kB pathway than the dominant-negative IKK2 mutant (Mercurio et al., 1997; Woronicz et al., 1997) . The IKKs function by mediating inducible phosphorylation and degradation of IkB proteins. In the case of IkBa, this phosphorylation occurs at serine residues 32 and 36, respectively (Brockman et al., 1995) . Mutation of these residues to alanine (IkBa S32/36A mutant) has been shown to render IkBa resistant to phosphorylation-induced degradation, resulting in a dominant-negative protein which can block NF-kB activation by diverse stimuli (Brockman et al., 1995) . As shown in Figure 3c , NFkB induction by ORF-K13 was eectively blocked by the IkBa S32/36A mutant suggesting that ORF-K13 activates NF-kB by inducible phosphorylation and degradation of IkB proteins.
ORF-K13 can block apoptosis induced by Death Domain-containing receptors independent of NF-kB activation As discussed before, MC159L and E8 have been previously shown to block cell death mediated by TNFR1, Fas and the TRAIL receptors DR4 (TRAIL-R1) and DR5 (TRAIL-R2) (Bertin et al., 1997; Hu et al., 1997a; Thome et al., 1997) . We were interested in the testing whether ORF-K13 possesses similar antiapoptotic property and the role of the NF-kB pathway in this process. Surprisingly, transient overexpression of ORF-K13 had a mild pro-apoptotic eect when it was expressed by itself in the 293T cells ( Figure 4 ). However, co-expression of ORF-K13 led to signi®cant inhibition of cell death mediated by TNFR1, Fas and DR4 in the 293T cells ( Figure 4 and data not shown). Co-expression of a phosphorylationresistant mutant of IkBa(IkBS32/36A) had no detrimental eect on the ability of ORF-K13 to block apoptosis induced by the above receptor ( Figure 4 ). On the contrary, co-expression of IkBS32/36A with ORF-K13 blocked cell death mediated by it and, furthermore, led to increased protection against TNFR1-mediated cell death ( Figure  4 ). These results are consistent with recent reports suggesting that depending on the cell type and the timing of its activation, NF-kB pathway may possess pro-or anti-apoptotic properties (Beg and Baltimore, 1996; Grimm et al., 1996; Hettmann et al., 1999; Hsu et al., 1996a,b; Jung et al., 1995; Liu et al., 1996; Van Antwerp et al., 1996; Wang et al., 1996) . Taken together, the above results suggest that activation of the NF-kB pathway is not essential for the ability of ORF-K13 to block death-receptors-induced cell death and may, in fact, stimulate cell death when ORF-K13 is over-expressed by itself.
Modulation of Caspase 8-and death domain receptorsinduced NF-kB activation by MC159L and E8
As discussed above, both MC159L and E8 failed to activate NF-kB in the 293T cells. We were next interested in determining whether MC159L could modulate NF-kB induction by Caspase 8 and its homologs. We have recently discovered that like their viral counterparts, cellular DEDs-containing proteins such as Caspase 8, 10 and MRIT can also activate the NF-kB pathway and a point mutant of the ®rst DED of Caspase 8 (Caspase 8 D73A) can block DDreceptors-induced NF-kB in an dominant-negative fashion (manuscript in preparation). As shown in Figure 5a , co-expression of MC159L led to eective inhibition of NF-kB induction by Caspase 10 and MRIT but failed to eectively block NF-kB induced by Caspase 8. Co-expression of MC159L also inhibited NF-kB induction by several DD-containing receptors of the TNFR family such as TNFR1, Fas/CD95, DR3 and DR4 (Figure 5b) . Thus, MC159L behaves like the L73A mutant of Caspase 8. However, we have noticed a slight dierence in the relative ability of MC159L and Caspase 8 D73A to block NF-kB induction by dierent death domain receptors. While MC159L is more ecient at blocking NF-kB induction by DR4, Caspase 8 D73A is more eective at blocking this activity induced by TNFR1 and DR3 (Figure 5b ). These results may re¯ect the relatively poor ability of MC159L to block Caspase 8-induced NF-kB activation and are in agreement with recent studies which suggest that Caspase 8 is primarily responsible for signal transduction via TNFR1, and DR3, but not via the TRAIL receptors DR4 and DR5 (Pan et al., 1997a,b) .
We also tested the ability of E8 to modulate NF-kB activation induced by Caspase 8 and its homologs. However, unlike MC159L, coexpression of E8 with the above cellular DEDs-containing proteins led to an increase in the activation of NF-kB ( Figure 5C ). Coexpression of E8 also led to a slight increase in the NF- ) were transfected with a control plasmid or a plasmid encoding TNFR1 (150 ng/well) along with a control plasmid or a plasmid encoding ORF-K13 (500 ng/well) in each well of a 24 well plate in duplicate. A plasmid encoding RSVLacZ was cotransfected as well. Twenty-four hours later, cells were ®xed, stained with X-gal, which stained the transfected cells blue. The per cent apoptotic cells were counted as the percentage of blue cells with dark rounded appearance, condensed nuclei and membrane blebs, as described previously kB activation induced by DD-containing receptors (data not shown). These results suggest that E8 might play a facilitatory role in the activation of the NF-kB pathway.
Physical interaction between viral DEDs-containing proteins and proteins of the kinase casade
To further de®ne the mechanism of NF-kB modulation by the various vFLIPs, we tested their ability to physically interact with various proteins involved in the NF-kB signal transduction pathway. All three vFLIPs could coimmunoprecipitate with TRAF1 and TRAF2 when overexpressed in the 293T cells (Figure 6a and data not shown). The interaction between ORF-K13 and TRAF1 and 2 was further con®rmed using yeast two-hybrid interaction assay, which ruled out the involvement of any intermediate protein in this interaction (not shown). All three vFLIPs could also coimmunoprecipitate with the serine threonine kinase RIP, which has been recently shown to be essential for TNFR1-induced NF-kB activation (Figure 6b ). However, only ORF-K13 could coimmunoprecipitate with NIK and IKK1 or 2 in the above assay, although a weak interaction between E8 and NIK was observed on prolonged exposure (Figure 6c and d and data not shown). Taken together, the above results suggest that the interaction of the DEDs-containing proteins with IKKs may be critical for the activation of the NF-kB pathway.
Discussion
The vFLIPs E8 and MC159L have been previously known to block cell death mediated by several death receptors belonging to the TNFR family (Bertin et al., 1997; Hu et al., 1997a; Thome et al., 1997) . In the present study we demonstrate that ORF-K13, a vFLIP encoded by HHV8, can similarly block apoptosis mediated by death receptors. However, unlike E8 and MC159L, ORF-K13 is also capable of activating the NF-kB pathway.
While all three vFLIPs tested in the current study could physically interact with RIP and TRAFs, only ORF-K13 could interact with the IKKs (and NIK). Similarly, we have recently discovered that while both the prodomain and the caspase domain of Caspase 8 could bind to RIP, NIK and TRAFs, only the NF-kB activating prodomain could interact with the IKKs (manuscript in preparation). Taken together, the above results indicate that the interaction with the IKK(s) may be critical for the activation of the NF-kB pathway by the vFLIPs. However, dominant-negative mutants of TRAF2 and NIK could block ORF-K13-induced NF-kB activation, which will indicate that the interactions of ORF-K13 with these proteins are functionally signi®cant as well. Therefore, a possible model for the NF-kB inducing ability of ORF-K13 may be based on the ability of this protein to bring together a number of dierent signaling proteins involved in the NF-kB activation pathway. A 700 ± 900 kDa signalsome complex was recently shown to contain many of the proteins involved in NF-kB signal transduction (DiDonato et al., 1997; Mercurio et al., 1997; Zandi et al., 1997) . Future studies should test whether ORF-K13 is part of such a signalsome complex. Based on the above model, the NF-kB inhibiting property of MC159L could be due to its ability to interact with only some proteins of the signalsome complex with the resultant disruption of the complex.
It is highly unlikely that the NF-kB inducing ability of ORF-K13 is due to overexpression-induced reverse signaling through a FADD-TRADD-RIP-TRAF2-NIK-IKKs complex due to the following reasons. First, we demonstrate that ORF-K13 can activate the NF-kB pathway in mouse embryonic ®broblasts derived from FADD7/7 mice. Second, while both MC159L and E8 can bind to FADD (Bertin et al., 1997; Hu et al., 1997a; Thome et al., 1997) , and RIP, they fail to activate the NF-kB pathway. Taken together, the above results suggest that the NF-kB inducing ability of ORF-K13 is due to its speci®c interaction(s) with the proteins of the kinase cascade and not due to an artifact of over-expression induced aggregation with them.
An unexpected ®nding of the current study was the mild pro-apoptotic property of ORF-K13 when transiently overexpressed in 293T cells by itself. Both MC159L and E8 lack such an ability (Bertin et al., 1997; Hu et al., 1997a; Thome et al., 1997 and our unpublished results) . However, like ORF-K13, the DEDs-containing prodomains of Caspase 8 and MRIT/cFLIP have been reported to induce apoptosis when over-expressed in mammalian cells Han et al., 1997; Shu et al., 1997) . We have recently discovered that the prodomains of Caspase 8 and MRIT/cFLIP, like ORF-K13, can also activate the NF-kB pathway (manuscript in preparation). Collectively, the above results suggest that the apoptosisinducing ability of ORF-K13 and the prodomains of Caspase 8 and MRIT/cFLIP may be related to their ability to activate the NF-kB pathway. This conclusion will be supported by the ability of IkBaS32/36A to block ORF-K13-induced cell death.
The NF-kB pathway is well known for its role in the transcriptional activation of several cytokine related genes, such as TNFa, TNFb, IL-1, IL-2, IL-6, and IL-8 (Baeuerle and Baichwal, 1997; Beauparlant and Hiscott, 1996) . Therefore, the NF-kB activating ability of ORF-K13 may have important implications for the natural history of Kaposi's Sarcoma (KS). One of the unique features of KS is the involvement of cytokines and growth factors in the pathogenesis of this disease (Gallo, 1998; Karp et al., 1996) . Indeed, a hallmark of this disease is abnormal angiogenesis that is driven in both autocrine and paracrine fashion by exuberant production of cytokines such as IL-1, TNF, IL-6, IL-8 and FGFs (Karp et al., 1996) . It has been suggested that KSHV/HHV8 causes KS by contributing to this cytokine dysregulation (Gallo, 1998; Karp et al., 1996) . In fact, KSHV has been shown to encode for a homolog of IL-6 (vIL6) as well as a constitutively active G-protein coupled receptor with homology to IL-8 receptor (reviewed in Moore et al., 1996; Schulz, 1998) . However, none of these genes are expressed in latently infected KS spindle cells, making it unlikely that they play a direct role in the abnormal cellular proliferation seen in KS (Moore et al., 1996; Schulz, 1998) . On the contrary, ORF-K13 is expressed in the latently infected KS spindle cells and, as such, is an ideal candidate for the growth promoting role of KSHV 8/HHV8 (Schulz, 1998) .
In addition to Kaposi Sarcoma, KSHV/HHV8 has been also implicated in the pathogenesis of several poorly characterized lymphadenopathies such as primary eusion lymphoma (PEL), multicentric Castleman's disease and angioimmunoblastic lymphadenopathy (reviewed in Brooks et al., 1997; Miles, 1996) . In this regard, it is noteworthy that another virus implicated in the pathogenesis of human lymphomas were transfected with expression vectors encoding FLAG-tagged vFLIPs (5 mg each) along with HA-tagged murine TRAF2 (5 mg). FLAG-tagged protetins were immunoprecipitated using beads containing an antibody against the FLAG-epitope (F) or an irrelevant mouse control antibody (C). The coimmunoprecipitating mTRAF2 was detected by Western blot analysis using a rabbit polyclonal antibody against the HA tag. (b) Interaction of vFLIPs with RIP. 293T cells were transfected with HA-tagged RIP (5 mg) and FLAG-tagged vFLIPs (5 mg each) and the experiment carried out essentially as described above. (c) ORF-K13 interacts with NIK where as MC159L and E8 fail to do so. 293T cells were transfected with HA-tagged NIK and Flag-tagged vFLIPs and the experiment carried out essentially as described above. A weak interaction between E8 and NIK was observed on prolonged exposure. Western blot on total cellular extracts is used to demonstrate that lack of immunoprecipatation of NIK with MC159L and E8 is not due to lack of expression of these proteins (lower panel). (d) ORF-K13 interacts with IKK2 where as MC159L and E8 fail to do so. Experiment was carried out essentially as described above for. A diuse band migrating with the IKK2 band in the control lane is due to the heavy chain of mouse immunoglobin. Western blot on total cellular extracts is used to demonstrate that lack of coimmunoprecipatation of IKK2 with MC159L and E8 is not due to lack of expression of these proteins (lower panel). Abbreviations used are F, Flag beads; C, control beads; L, total cellular lysate; I.P., immunoprecipitation is the Epstein-Barr Virus and recent studies have implicated abnormal NF-kB activation by virally encoded LMP1 protein in the pathogenesis of this disease as well (Schulz, 1998) . Abnormal NF-kB activation has also been implicated in the cellular transformation by human T-cell leukemia virus type I (HTLV-I) and rearrangement and/or ampli®cation of the genes encoding Rel/IkB factors has been detected in as many as 20 ± 25% of several human lymphoid tumors (Gilmore et al., 1996; Mosialos, 1997; Schulz, 1998) . The above studies suggest that lymphohematopoietic cells may be abnormally susceptible to transformation induced by abnormal NF-kB activation and that activation of this pathway by ORF-K13 may play a role in the pathogenesis of lymphoid disorders associated with infection by the KSHV. This conclusion is supported by the fact that, like the KS spindle cells, ORF-K13 is also expressed in latently infected PEL cell lines (Rainbow et al., 1997; Sarid et al., 1998; Schulz, 1998; ) .
The inhibitory eect of MC159L on NF-kB activation by DD-containing receptors might play a role in the persistence of clinical infection by the MCV. Infection by MCV leads to epidermal hyperplasia (reviewed in Birthistle and Carrington, 1997) . A hallmark of the infection is an almost complete lack of in¯ammation in the aected areas which might allow the infection to persist for months to years and also contributes to its recurrence after treatment (Birthistle and Carrington, 1997) . Cell-mediated immunity does not play an important role in the immune response to this infection and there is a complete lack of immunologically competent cells in the viral lesions (Birthistle and Carrington, 1997) . The mechanism by which MCV blocks the local immune and inflammatory response is not known at present. However, based on the known importance of the NF-kB pathway in the activation of the in¯ammatory response, it is possible that MC159L-induced inhibition of this pathway may play a causative role in the lack of in¯ammatory and immune response seen in clinical infection with MCV. Therapeutic agents blocking the action of the MC159L protein may be useful in invoking an in¯ammatory response to this virus.
Materials and methods

Cell lines and reagents
FADD7/7 cells derived from gestation age 9.5 days embryos were provide by Dr Tak Mak. 293T cells were obtained from Dr David Han (University of Washington, Seattle, WA, USA). 293EBNA and NIH3T3 cells were obtained from Invitrogen and ATCC, respectively. Rabbit polyclonal antibodies against FLAG, HA and MYC tags were obtained from Santa Cruz Laboratories. Flag beads were obtained from Kodak Scienti®c Imaging Systems.
Expression constructs
The expression constructs for the death receptors, RIP, Caspase 8, CrmA, MRIT, E8 and MC159L have been described previously Han et al., 1997; Hu et al., 1997a) . Constructs encoding ORF-K13 (GenBank U90534) were prepared by PCR ampli®cation of the desired coding sequence from a human genomic DNA sample containing KSHV/HHV8 (human herpesvirus 8) genomic DNA which was obtained from Dr Tim Rose (University of Washington, Seattle, WA, USA). Primers for PCR ampli®cation were 5' CCGCGGGATCCACATGGC-CACTTACGAGGTTCTC 3' (forward primer) and 5' CGCGGCTCGAGTGGTGTATGGCGATAGTGTTG 3' (reverse primer) and carried additional sequences at their 5' end for subsequent restriction digestion and cloning of the ampli®ed insert. The ampli®ed PCR product was digested with BamHI and XhoI and cloned inframe in to a modi®ed pcDNA3 vector (Invitrogen) carrying a C-terminal Flagepitope tag. Constructs encoding NIK and its mutants (Natoli et al., 1997) , IKKs and their mutants (Nakano et al., 1998) , IkBa S32/36A (Brockman et al., 1995) , Caspase 10 (Mch4 isoform) and its C358A mutant (Fernandes-Alnemri et al., 1996) and NF-kB/luciferase reporter (Berberich et al., 1994) have been described previously and were obtained from the indicated sources. The various point mutants of ORF-K13 and Caspase 8 were generated using the Quickchange site-directed mutagenesis kit (Stratagene). Epitope-tagged expression constructs for the vFLIPs, TRAFs and RIP were tagged at the C-termini using custom primers. The sequence of all constructs was con®rmed by automated¯uorescent dyeterminator sequencing on an ABI 373 sequencing machine. Expression of all constructs was con®rmed by Western analysis on total cell extracts.
NF-kB luciferase reporter assay
For reporter gene assay, 1610 5 293T cells were seeded in each well of a 24-well tissue culture plate. Twenty-four hours later cells were transfected in duplicate using calcium phosphate with the indicated amounts of various expression constructs along with an NF-kB/luciferase reporter construct (75 ng) and an RSV promoter driven b-galactosidase reporter construct (pRcRSV/LacZ) (75 ng). The NF-kB reporter plasmid contains four copies of an NF-kB binding site from the the promoter of the invariant chain of MHC class II and has been described previously (Berberich et al., 1994) . Western blot analysis on cell extracts prepared from similarly transfected cells was used to con®rm that the various expression constructs lead to the production of the desired proteins. Twenty to thirty-six hours later cell extracts were prepared using the Luciferase Cell Culture Lysis Reagent (Promega, Madison, WI, USA) and luciferase assays performed using 20 ml of cell extract. The cell lysate was diluted 1 : 20 with Phosphate Buered Saline (pH=7.4) and used for measurement of b-galactosidase activity. Luciferase activity was normalized relative to the bgalactosidase activity to control for the dierence in the transfection eciency. Essentially the same procedure was obtained for experiments involving the NIH3T3 and FADD7/7 mouse embryonic ®broblasts, except Fugene6 (Boehringer Mannheim) was used for transfection and the luciferase assay was carried out 36 h post-transfection.
Coimmunoprecipitation assays
For studying in vivo interaction, 2610 6 293T cells were plated in a 100 mm plate and co-transfected 18 ± 24 h later with 5 mg/plate of each epitope-tagged constructs along with 1 mg of a GFP-encoding plasmid (pEGFP or HA-GFP) by calcium phosphate co-precipitation. Eighteen to thirty-six hours post-transfection, cells were lysed in 1 ml of lysis buer containing 0.1% Triton-X 100, 20 mM sodium phosphate (pH 7.4), 150 mM NaCl and 1 EDTA free mini-protease inhibitor tablet per 10 ml (Boehringer Mannheim). For immunoprecipitation, cells lysate (500 ml) was incubated for 1 h at 48C with 10 ml of FLAG or control mouse Ig beads. Beads were washed twice with lysis buer, once with a wash buer containing 0.1% Triton-X 100, 20 mM sodium phosphate (pH 7.4), 500 mM NaCl and again with lysis buer. Bound proteins were eluted by boiling, separated by SDS ± PAGE, transferred to a nitrocellulose membrane and analysed by Western blot.
Electrophoretic mobility shift assay
293T cells were (3610 5 ) were transfected with 2 mg of various constructs in each well of a 6-well plate. After 16 h, nuclear extracts were prepared essentially as described previously (Yeh et al., 1997) . Nuclear extracts (2 mg) were incubated for 30 min at room temperature with a 32 P-labeled NF-kB duplex oligonucleotide (Promega, Madison, WI, USA) in a buer containing 10 mM HEPES (pH 7.9); 50 mM KCl, 0.2 mM EDTA, 2.5 mM DTT, 2 mg poly (dC:dI), 10% glycerol and 0.5% NP-40. Competition was carried out with 100-fold excess of cold NF-kB oligo duplex or a non-speci®c oligo duplex. Gel super-shift assay was performed with 1 ml of various subunit speci®c or control antibodies. Protein-DNA complexes were resolved on a 5% native polyacrylamide and run in Tris-glycine buer. Gel was dried and autoradiographed.
